LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On May9, 2017, Loxo Oncology,Inc. (Loxo Oncology)
issued a press release announcing its financial results for the
quarterly period ended March31, 2017. A copy of the press release
is attached as Exhibit99.01 to this Current Report on Form8-K.
The information in this Item2.02, including Exhibit99.01 to this
Current Report on Form8-K, shall not be deemed to be filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that section
or Sections11 and 12(a)(2)of the Securities Act of 1933, as
amended. The information contained in this Item2.02 and in the
accompanying Exhibit99.01 shall not be incorporated by reference
into any registration statement or other document filed by Loxo
Oncology with the Securities and Exchange Commission, whether
made before or after the date of this Current Report on Form8-K,
regardless of any general incorporation language in such filing
(or any reference to this Current Report on Form8-K generally),
except as shall be expressly set forth by specific reference in
such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
|
99.01 |
Press release issued by Loxo Oncology regarding its |
About LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Larotrectinib, formerly referred to as LOXO-101, is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. TRK fusions have been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-195 is a drug candidate in preclinical development. It was designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor, such as larotrectinib, or multikinase inhibitors with anti-TRK activity. LOXO ONCOLOGY, INC. (NASDAQ:LOXO) Recent Trading Information
LOXO ONCOLOGY, INC. (NASDAQ:LOXO) closed its last trading session down -0.33 at 43.94 with 168,100 shares trading hands.